Pharmacogenetics of antiretroviral therapy (Q38221179)

31 August 2017

Pharmacogenetics of antiretroviral therapy (English)

1 reference

31 August 2017

anti-retroviral agent

0 references

5

Vincent Soriano

1 reference

31 August 2017

Pablo Barreiro

1

1 reference

31 August 2017

José Vicente Fernández-Montero

series ordinal

2

1 reference

31 August 2017

Carmen de Mendoza

series ordinal

3

1 reference

31 August 2017

Pablo Labarga

series ordinal

4

1 reference

31 August 2017

language of work or name

English

0 references

publication date

18 June 2014

1 reference

Expert Opinion on Drug Metabolism & Toxicology

31 August 2017

1 reference

31 August 2017

10

1 reference

31 August 2017

1119-1130

1 reference

31 August 2017

8

1 reference

Pharmacogenetics and adverse drug reactions

31 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

Some statistical data on atypical cholinesterase of human serum

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

Pharmacogenomics--drug disposition, drug targets, and side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

Pharmacogenetic perspectives gained from twin and family studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

P-glycoprotein and multidrug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

A review of the pharmacokinetics of abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

Pharmacogenetic characteristics of indinavir, zidovudine, and lamivudine therapy in HIV-infected adults: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

The abacavir hypersensitivity reaction: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

HLA-B*5701 screening for hypersensitivity to abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

Prospective screening for human leukocyte antigen-B*5701 avoids abacavir hypersensitivity reaction in the ethnically mixed French HIV population

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

Successful implementation of a national HLA-B*5701 genetic testing service in Canada.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

Prospective HLA-B*5701 screening and abacavir hypersensitivity: a single centre experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

Use of the HCP5 single nucleotide polymorphism to predict hypersensitivity reactions to abacavir: correlation with HLA-B*5701.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

Fanconi syndrome and renal failure induced by tenofovir: a first case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

Bone mineral density effects of randomized regimen and nucleoside reverse transcriptase inhibitor selection from ACTG A5142.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

Mechanism of active renal tubular efflux of tenofovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

Human organic anion transporter MRP4 (ABCC4) is an efflux pump for the purine end metabolite urate with multiple allosteric substrate binding sites.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

Multidrug resistance-associated protein 2 (MRP2) affects hepatobiliary elimination but not the intestinal disposition of tenofovir disoproxil fumarate and its metabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

Genetic variants of ABCC10, a novel tenofovir transporter, are associated with kidney tubular dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

Association of noncirrhotic portal hypertension in HIV-infected persons and antiretroviral therapy with didanosine: a nested case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

Genetic determinants of idiopathic noncirrhotic portal hypertension in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

Genetics of the variable expression of CYP3A in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

Short communication: interactions between nevirapine plasma levels, chronic hepatitis C, and the development of liver toxicity in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

Changes in nevirapine plasma concentrations over time and its relationship with liver enzyme elevations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

Associations between CYP2B6 polymorphisms and pharmacokinetics after a single dose of nevirapine or efavirenz in African americans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

CYP2B6 polymorphism and nonnucleoside reverse transcriptase inhibitor plasma concentrations in Chinese HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

Nevirapine-induced hepatotoxicity and pharmacogenetics: a retrospective study in a population from Mozambique

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

Cytochrome P450 2B6 (CYP2B6) G516T influences nevirapine plasma concentrations in HIV-infected patients in Uganda

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

Cytochrome P450 2B6 516G-->T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

Hepatotoxicity of nevirapine in virologically suppressed patients according to gender and CD4 cell counts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

HLA-DRB1*01 associated with cutaneous hypersensitivity induced by nevirapine and efavirenz

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

HLA-dependent hypersensitivity to nevirapine in Sardinian HIV patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

Associations between HLA-DRB1*0102, HLA-B*5801, and hepatotoxicity during initiation of nevirapine-containing regimens in South Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

HLA-B*3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

Analyzing sleep abnormalities in HIV-infected patients treated with Efavirenz

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

Glucuronidation of the antiretroviral drug efavirenz by UGT2B7 and an in vitro investigation of drug-drug interaction with zidovudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

Multiple novel nonsynonymous CYP2B6 gene polymorphisms in Caucasians: demonstration of phenotypic null alleles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

A natural CYP2B6 TATA box polymorphism (-82T--> C) leading to enhanced transcription and relocation of the transcriptional start site.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

High prevalence of the CYP2B6 516G-->T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

CYP2B6 983T>C polymorphism is prevalent in West Africa but absent in Papua New Guinea: implications for HIV/AIDS treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

Polymorphic variants of cytochrome P450 2B6 (CYP2B6.4-CYP2B6.9) exhibit altered rates of metabolism for bupropion and efavirenz: a charge-reversal mutation in the K139E variant (CYP2B6.8) impairs formation of a functional cytochrome p450-reductase c

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

Efavirenz in the therapy of HIV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

Successful use of reduced-dose efavirenz in a patient with human immunodeficiency virus infection: case report and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

Partial deletion of CYP2B6 owing to unequal crossover with CYP2B7.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

Haplotype structure of CYP2B6 and association with plasma efavirenz concentrations in a Chilean HIV cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

Multilocus genetic interactions and response to efavirenz-containing regimens: an adult AIDS clinical trials group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

The effects of protease inhibitors and nonnucleoside reverse transcriptase inhibitors on p-glycoprotein expression in peripheral blood mononuclear cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

Association of human liver bilirubin UDP-glucuronyltransferase activity with a polymorphism in the promoter region of the UGT1A1 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

Pharmacogenetics of Gilbert's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

Genetic factors influencing severe atazanavir-associated hyperbilirubinemia in a population with low UDP-glucuronosyltransferase 1A1*28 allele frequency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

Switch from ritonavir-boosted to unboosted atazanavir guided by therapeutic drug monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

Population pharmacokinetics of atazanavir in human immunodeficiency virus-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

Predictors of virological response to atazanavir in protease inhibitor-experienced patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C-->T polymorphism at the multidrug resistance gene 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C-->T) with reduced concentrations of unboosted atazanavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

Population pharmacokinetic modeling of the association between 63396C->T pregnane X receptor polymorphism and unboosted atazanavir clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

Efficacy and safety of atazanavir-ritonavir plus abacavir-lamivudine or tenofovir-emtricitabine in patients with hyperlipidaemia switched from a stable protease inhibitor-based regimen including one thymidine analogue

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

Improved metabolic profile after switch to darunavir/ritonavir in HIV positive patients previously on protease inhibitor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

The end of AIDS: HIV infection as a chronic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

Hypertriglyceridemia in the acquired immunodeficiency syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

Modeling the influence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

Dyslipidemia in HIV-infected individuals: from pharmacogenetics to pharmacogenomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

Contribution of 20 single nucleotide polymorphisms of 13 genes to dyslipidemia associated with antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

Contribution of genome-wide significant single-nucleotide polymorphisms and antiretroviral therapy to dyslipidemia in HIV-infected individuals: a longitudinal study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

Pharmacokinetics of raltegravir in individuals with UGT1A1 polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

Population pharmacokinetic analysis and pharmacogenetics of raltegravir in HIV-positive and healthy individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

Genetic and non-genetic determinants of raltegravir penetration into cerebrospinal fluid: a single arm pharmacokinetic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

High interpatient variability of raltegravir CSF concentrations in HIV-positive patients: a pharmacogenetic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

Dolutegravir, abacavir and lamivudine as HIV therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

Evaluation of the effect of cobicistat on the in vitro renal transport and cytotoxicity potential of tenofovir.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

Pharmacogenetics, pharmacogenomics, and individualized medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

Genomic medicine--an updated primer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

The predictive capacity of personal genome sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

Influence of polymorphisms within the CX3CR1 and MDR-1 genes on initial antiretroviral therapy response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

Pharmacogenetics-based population pharmacokinetic analysis of etravirine in HIV-1 infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

Drug Transporter and Metabolizing Enzyme Gene Variants and Nonnucleoside Reverse-Transcriptase Inhibitor Hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

Switching to unboosted atazanavir reduces bilirubin and triglycerides without compromising treatment efficacy in UGT1A1*28 polymorphism carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.930128

10.1517/17425255.2014.930128

21 January 2018

Identifiers

DOI

1 reference

release_wux2voy4mjdhhmurji36d3k2ju

31 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/wux2voy4mjdhhmurji36d3k2ju

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference